Q32 Bio Inc (QTTB)
NASDAQ:QTTB
Want to see QTTB full AI Analyst Report?
QTTB Stock Chart & Stats
$5.85
-$0.23(-6.52%)
At close: 4:00 PM EST
$5.85
-$0.23(-6.52%)
Day’s Range― - ―
52-Week Range$1.35 - $14.85
Previous CloseN/A
Volume113.57K
Average Volume (3M)1.16M
Market Cap
$215.35M
Enterprise Value$101.42M
Total Cash (Recent Filing)$50.75M
Total Debt (Recent Filing)$10.99M
Price to Earnings (P/E)5.4
Beta0.45
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.68
Shares Outstanding16,956,415
10 Day Avg. Volume862,702
30 Day Avg. Volume1,159,724
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.22
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue1.89
Enterprise Value/Gross Profit1.90
Enterprise Value/Ebitda4.58
Forecast
1Y Price Target
$12.33Price Target Upside110.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profitability ImprovementThe company’s sharp step-up to positive operating and net margins indicates the business model can generate high incremental profitability from current revenue streams. If sustained, these margins improve funding flexibility for clinical programs and reduce reliance on external financing over the medium term.
Improving Balance SheetMarked reduction in leverage and a meaningful equity and asset base materially strengthen financial stability. Lower debt reduces refinancing risk and interest burden, giving management more runway to advance clinical trials and negotiate partnerships without immediate solvency pressure.
Institutional Financing SupportA $55M placement led by specialized healthcare investors provides not just capital but validation and potential follow-on support. This structured financing materially improves near-term runway to advance the Phase 2 program and de-risks clinical milestones versus peers lacking institutional backers.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow (~-$27.4M TTM) means the company is not self-funding development and must access external capital to sustain operations. Over the medium term this raises execution risk and increases probability of dilutive financings during clinical-stage development.
Flat And Volatile RevenueFlat revenues and historical volatility reduce confidence that recent margin gains are durable. For a clinical-stage biotech, inconsistent topline trends make it harder to rely on operating profits to fund R&D, increasing sensitivity to trial outcomes and external funding cycles.
Financing Dependence / Dilution RiskExpanded ATM capacity and recent placements show clear reliance on equity markets for capital. Long-term dependence on equity raises dilution risk for shareholders and can pressure strategic decision-making, as management may prioritize capital-raising flexibility over alternative non-dilutive paths.
Q32 Bio News
QTTB FAQ
What was Q32 Bio Inc’s price range in the past 12 months?
Q32 Bio Inc lowest stock price was $1.34 and its highest was $14.85 in the past 12 months.
What is Q32 Bio Inc’s market cap?
Q32 Bio Inc’s market cap is $215.35M.
When is Q32 Bio Inc’s upcoming earnings report date?
Q32 Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 54 days.
How were Q32 Bio Inc’s earnings last quarter?
Q32 Bio Inc released its earnings results on May 05, 2026. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.68 by $0.14.
Is Q32 Bio Inc overvalued?
According to Wall Street analysts Q32 Bio Inc’s price is currently Undervalued.
Does Q32 Bio Inc pay dividends?
Q32 Bio Inc does not currently pay dividends.
What is Q32 Bio Inc’s EPS estimate?
Q32 Bio Inc’s EPS estimate is -0.56.
How many shares outstanding does Q32 Bio Inc have?
Q32 Bio Inc has 16,956,415 shares outstanding.
What happened to Q32 Bio Inc’s price movement after its last earnings report?
Q32 Bio Inc reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.68. Following the earnings report the stock price went up 1.984%.
Which hedge fund is a major shareholder of Q32 Bio Inc?
Currently, no hedge funds are holding shares in QTTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Q32 Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (110.83% Upside)
$12.33 (110.83% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $30.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 37.7%
Last 30 Days ▲ 37.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
647.05%
12-Months-Change
Fundamentals
Return on Equity
230.68%
Trailing 12-Months
Asset Growth
-19.47%
Trailing 12-Months
Company Description
Q32 Bio Inc
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
QTTB Stock 12 Month Forecast
Average Price Target
$12.33
▲(110.83% Upside)
Technical Analysis
Tempest Therapeutics
―
PDS Biotechnology
―
Grace Therapeutics
―
CalciMedica
―
Senti Biosciences
―
Ownership Overview
10.01% Insiders
2.71% Mutual Funds
48.01% Other Institutional Investors
36.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---